Skip to main content
. 2018 Nov 15;10(11):446. doi: 10.3390/cancers10110446

Figure 6.

Figure 6

In vivo antibody depletion reduces the antitumor effect of the ADSC-E7’-eGFP–PE(ΔIII)-E7-KDEL3 combined treatment. (A) Time course of the experiment; (B) tumor volume measurements of syngeneic tumor models with different treatments were conducted at indicated days after the subcutaneous injection of CT26 cells; * p < 0.05 using two-way ANOVA.